Austin, TX – November 21, 2024 – Pattern Bioscience, an innovator in rapid diagnosis and antibiotic susceptibility testing for bacterial infections, today announced it has been awarded a cost-share contract worth up to $40.9 million by the Biomedical Advanced Research...
AUSTIN, Texas — July 31, 2023 — Pattern Bioscience, Inc., an innovator in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, today announced that it was named the winner of the Disruptive Technology Award from the Association for...
New funding will be used to accelerate development of first-of-its-kind infectious disease diagnostic platform that will deliver rapid antibiotic treatment guidance AUSTIN, Texas — April 27, 2023 — Pattern Bioscience, Inc., an innovator in rapid diagnosis and...
Renowned microbiologist will bring clinical expertise as the company advances its platform for rapid pathogen identification and antibiotic susceptibility testing AUSTIN, Texas — March 10, 2022 — Pattern Bioscience, Inc., developer of Digital Culture™ technology for...
AUSTIN, Texas, December 8, 2021 – Pattern Bioscience, Inc. has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Pneumonia Action Panel. The test uses Pattern’s Digital CultureTM technology to provide a fast and...
Led by Illumina Ventures, the Series B-1 round will accelerate development and validation of transformational bacterial testing technology AUSTIN, Texas, July 14, 2020 – Pattern Bioscience, Inc. today announced $9M in additional funding to accelerate the development...
